Enliven Therapeutics, Inc. Common Stock Earnings Dividend

Enliven Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2026. On a quarterly growth basis, Enliven Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.

Enliven Therapeutics, Inc. Common Stock’s net profit jumped 17.23% since last year same period to $-23.63Mn in the Q1 2026. On a quarterly growth basis, Enliven Therapeutics, Inc. Common Stock has generated 20.36% jump in its net profits since last 3-months.

Enliven Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2026. On a quarterly growth basis, Enliven Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.

Enliven Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.4 - a 2.44% jump from last quarter’s estimates.

Enliven Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.4.

Enliven Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 33.33% since last year same period to -0.38 in the Q1 2026. This indicates that the Enliven Therapeutics, Inc. Common Stock has generated 33.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Enliven Therapeutics, Inc. Common Stock’s return on assets (ROA) stands at -0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Enliven Therapeutics, Inc. Common Stock’s return on equity (ROE) stands at -0.27.